Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07258849 | A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis | PHASE1 | RECRUITING | 141 | — | — | Dec 2, 2025 | Mar 1, 2028 | May 22, 2026 | 10 | United States, Germany |
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4213663 (Part A) | EXPERIMENTAL | Single-ascending dose (SAD) of LY4213663 administered subcutaneously (SC) and intravenously (IV) in healthy participants |
| Placebo (Part A) | PLACEBO_COMPARATOR | SAD placebo administered SC and IV |
| LY4213663 (Part B) | EXPERIMENTAL | Multiple-ascending doses (MAD) of LY4213663 administered SC and IV in healthy participants |
| Placebo (Part B) | PLACEBO_COMPARATOR | MAD placebo administered SC and IV |
| LY4213663 (Parts C and D) | EXPERIMENTAL | Multiple doses of LY4213663 administered SC and IV in participants with RA |
| Name | Type | Description |
|---|---|---|
| LY4213663 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Have a body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m²), inclusive Part C and D Only: * Have a body weight at least 50 kilograms and BMI within the range 18.0 to 40.0 kg/m² (inclusive) at screening * Have a diagnosis of adult-onset RA for at least 3 mo...